Impact of Volume-based Procurement of Drugs on Clinical Usage of Oral Antineoplastic Drugs in a Hospital
Objective To explore the influence of volume-based procurement on the use of oral antineoplastic drugs in a hospital and to provide data for decision-makers.Methods The frequency of drug use,defined daily cost and actual cost saved related to oral antineoplastic drugs used in the same period(from May 20 to December 31 in 2019,2020 and 2021)before and after implementation of the volume-based procurement policy were dynamically analyzed.Results Except sorafenib mesylate tablets whose price was not adjusted,the prices of other drugs were lowered to varying extents,with decreases ranging from 12.00%to 76.01%after the implementation of the policy.In 2020,except for the frequency of use of imatinib that increased by 20%compared with 2019,the rest of the selected drugs showed a downward trend,with decreases between 6.35%and 86.96%.In 2021 two years after the implementation of the poli-cy,the frequency of use of the selected drugs trended up with increases of 10.71%to 500.00%except tegafur and sorafenib tosylate tablets,the frequency of which decreased by 57.43%and 46.10%,respec-tively.The defined daily cost of selected drugs decreased between 1.42%and 82.79%in 2020 and contin-ued to decline between 61.94%and 99.67%in 2021.After the implementation of the policy,the cost of oral antineoplastic drugs trended down year by year.The actual drug cost saved totaled 2.2740 million yuan in 2020 and 5.8817 million yuan in 2021.Conclusion The implementation of the volume-based procurement policy is of great significance for reducing the financial burden of cancer patients,but the clini-cal application of selected drugs needs to be optimized while the implementation of the policy needs to be supervised.
drug volume-based procurementoral antitumor agentsdefined daily dosesdefined daily cost
NETL
NSTL
万方数据
